22157.jpg
Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:57 ET | Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
logo.jpg
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
October 10, 2024 08:00 ET | Samsung Bioepis
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
logo.jpg
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
July 11, 2024 08:00 ET | Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
Coherus_Logo_RGB_150.png
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 27, 2024 08:26 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
22157.jpg
US HUMIRA Market Projected for Extensive Growth by 2032 in Noninfectious Autoimmune Uveitis Sector
February 28, 2024 11:05 ET | Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. An insightful analysis...
Global Dupuytren’s Disease Market
Global Dupuytren's Disease Research Report 2023: A $5.87 Billion Market by 2030 - Injectable Collagenase Therapies Revolutionize Contracture Management
December 11, 2023 09:18 ET | Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Dupuytren's Disease Market Size, Share & Trends Analysis Report By Type (Diagnosis, Treatment), By Disease Type (Type I, Type II), By End-use...
Amgen’s Amjevita Rem
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
September 14, 2023 11:37 ET | Spherix Global Insights
Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...
Rani-Logo.jpg
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
August 11, 2023 16:05 ET | Rani Therapeutics, LLC
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three...
Rani-Logo.jpg
Rani Therapeutics to Participate in August Investor Conferences
August 04, 2023 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
YUSIMRY™ (adalimumab-aqvh) product image
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
July 13, 2023 08:30 ET | Coherus BioSciences, Inc.
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to HumiraInnovative...